You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 4
  • EPV255/#120 Tisotumab vedotin vs investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovatv 301/ENGOT-CX12/GOG-3057, trial in progress)

Article metrics

Article menu

Download PDFPDF

E-Posters
E-Poster Viewing
EPV255/#120 Tisotumab vedotin vs investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovatv 301/ENGOT-CX12/GOG-3057, trial in progress)

 

Online download statistics by month:

Online download statistics by month: November 2021 to April 2024

AbstractFullPdf
Nov 202162018
Dec 202160014
Jan 20223308
Feb 20222501
Mar 20222005
Apr 202219010
May 202211010
Jun 20221905
Jul 20222105
Aug 20222607
Sep 20222606
Oct 20221508
Nov 20222902
Dec 20221904
Jan 20233005
Feb 20232801
Mar 20231002
Apr 20232205
May 20231402
Jun 20233002
Jul 20233305
Aug 20234502
Sep 20232002
Oct 20232504
Nov 20234402
Dec 20235702
Jan 20242400
Feb 20241807
Mar 20241306
Apr 2024702
Total8050152